IL158181A0 - N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity - Google Patents

N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Info

Publication number
IL158181A0
IL158181A0 IL15818102A IL15818102A IL158181A0 IL 158181 A0 IL158181 A0 IL 158181A0 IL 15818102 A IL15818102 A IL 15818102A IL 15818102 A IL15818102 A IL 15818102A IL 158181 A0 IL158181 A0 IL 158181A0
Authority
IL
Israel
Prior art keywords
prevention
treatment
methods
drug toxicity
acetylcysteine compositions
Prior art date
Application number
IL15818102A
Other languages
English (en)
Original Assignee
Bioadvantex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26960383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158181(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioadvantex Pharma Inc filed Critical Bioadvantex Pharma Inc
Publication of IL158181A0 publication Critical patent/IL158181A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15818102A 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity IL158181A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28060001P 2001-03-30 2001-03-30
US09/833,228 US6566401B2 (en) 2001-03-30 2001-04-11 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
PCT/US2002/009442 WO2002078627A2 (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Publications (1)

Publication Number Publication Date
IL158181A0 true IL158181A0 (en) 2004-03-28

Family

ID=26960383

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15818102A IL158181A0 (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
IL158181A IL158181A (en) 2001-03-30 2003-09-30 Pharmaceutical compositions consisting essentially of n-acetylcysteine and an oxidative therapeutic agent to prevent drug toxicity in mammals and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158181A IL158181A (en) 2001-03-30 2003-09-30 Pharmaceutical compositions consisting essentially of n-acetylcysteine and an oxidative therapeutic agent to prevent drug toxicity in mammals and uses thereof

Country Status (13)

Country Link
US (2) US6566401B2 (da)
EP (1) EP1379232B1 (da)
JP (3) JP2005508840A (da)
CN (1) CN100464743C (da)
AU (1) AU2002255942B2 (da)
BR (1) BR0208563A (da)
CA (1) CA2442168C (da)
ES (1) ES2550094T3 (da)
IL (2) IL158181A0 (da)
MX (1) MXPA03008904A (da)
NZ (1) NZ528478A (da)
RU (1) RU2291689C2 (da)
WO (1) WO2002078627A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662863B2 (en) * 2003-06-09 2010-02-16 Alan Andrews Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion
EP1874353A1 (en) 2005-04-05 2008-01-09 Yale University Glutamate modulating agents in the treatment of mental disorders
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
US20090298923A1 (en) * 2008-05-13 2009-12-03 Genmedica Therapeutics Sl Salicylate Conjugates Useful for Treating Metabolic Disorders
WO2010106083A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
WO2010106082A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
US20110014285A1 (en) * 2009-07-15 2011-01-20 Herzenberg Leonore A N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
US20140135396A1 (en) * 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
US8747894B2 (en) 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
WO2013175479A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity
TW202348234A (zh) 2013-12-24 2023-12-16 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
US10682324B2 (en) 2015-01-27 2020-06-16 Florengale, Llc Healing topical composition
JP2018524287A (ja) * 2015-05-27 2018-08-30 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 造影後の膵炎のリスクを低下させるための組成物及び方法
EP3302459A4 (en) 2015-05-28 2019-02-20 Baylor College of Medicine ADVANTAGES OF SUPPLEMENT WITH N-ACETYLCYSTEIN AND GLYCIN TO IMPROVE THE GLUTATHION MIRRORS
EP3402475B1 (en) * 2016-01-11 2021-10-20 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
EP3411047B1 (en) * 2016-02-04 2021-04-14 Czap Research And Development, LLC Controlled-release and stratified cyclodextrin inclusion complex vehicles
WO2018108960A1 (en) 2016-12-15 2018-06-21 Zambon S.P.A. N-acetylcysteine for use as antibacterial agent
EP3574894B1 (en) * 2017-01-24 2023-10-04 Woosung Pharmaceutical Co., Ltd. Injection composition containing acetaminophen
WO2020129509A1 (ja) * 2018-12-21 2020-06-25 富士フイルム株式会社 光毒性または光アレルギーの測定方法および上記測定方法において使用するための試薬
US11590090B2 (en) 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1141406B (it) * 1980-04-01 1986-10-01 Dob Far Spa Sali della cefapirina con aminoacidi
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
DE3616923A1 (de) 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
IT1248995B (it) * 1990-06-26 1995-02-11 Italfarmaco Spa Composizioni farmaceutiche a base di sali ferrosi
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
US5475757A (en) * 1994-06-07 1995-12-12 At&T Corp. Secure data transmission method
AU4399396A (en) * 1994-12-19 1996-07-10 Russinsky Limited Compounds
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
FR2744917B1 (fr) 1996-02-16 1998-04-10 Kouchner Gerard Composition therapeutique a base d'acetaminophene
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
EA200000087A1 (ru) * 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
EP1141318B1 (en) * 1999-01-04 2006-07-05 Innovata PLC P450 / acetaminophen gdept for cancer treatment
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols

Also Published As

Publication number Publication date
CA2442168C (en) 2012-05-29
BR0208563A (pt) 2006-02-21
US20020142991A1 (en) 2002-10-03
US20030069311A1 (en) 2003-04-10
RU2291689C2 (ru) 2007-01-20
JP2005508840A (ja) 2005-04-07
US7723389B2 (en) 2010-05-25
EP1379232A2 (en) 2004-01-14
EP1379232A4 (en) 2008-04-23
MXPA03008904A (es) 2005-03-07
IL158181A (en) 2012-04-30
JP2015078185A (ja) 2015-04-23
CN1507350A (zh) 2004-06-23
AU2002255942B2 (en) 2007-07-05
CN100464743C (zh) 2009-03-04
RU2003131876A (ru) 2005-04-10
WO2002078627A3 (en) 2003-09-18
EP1379232B1 (en) 2015-07-29
NZ528478A (en) 2007-08-31
WO2002078627A2 (en) 2002-10-10
CA2442168A1 (en) 2002-10-10
ES2550094T3 (es) 2015-11-04
US6566401B2 (en) 2003-05-20
JP2011225610A (ja) 2011-11-10

Similar Documents

Publication Publication Date Title
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
AU6147401A (en) Compositions and methods for the treatment of cancer
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
HK1048066A1 (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
WO2004006858A3 (en) Compounds, compositions, and methods employing same
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
IL164022A0 (en) Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
AU2003291480A8 (en) Composition for the prevention and treatment of inflammation of the ear
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
HK1082923A1 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HK1062810A1 (en) Use of il-18 inhibitors for the manufacture of medicaments for treatment and/or prevention of heartdisease
AU2002247973A1 (en) Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
PL368035A1 (en) Compositions and methods for the treatment of cancer
AUPR809001A0 (en) Compositions for the treatment and prevention of plant pathogens
AU2003285883A8 (en) Methods and compositions for determining risk of treatment toxicity
EP1551456A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RENAL DISEASES
EP1305017A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
AU2003251751A8 (en) Agents capable of inhibiting ras and uses thereof
SI1569929T1 (sl) Spojine in postopki za zdravljenje ali preprečevanje flavivirusnih infekcij
EP1557169A4 (en) THERAPEUTIC AND / OR PROPHYLACTIC AGENT FOR DYSCHEZIA
AU2003214606A8 (en) Compositions and methods for treating mdma-induced toxicity
IL151658A0 (en) Methods and compositions for the treatment or prevention of cardiovascular diseases